CASR and neoplasm: To determine whether targeting FIH may be a therapeutic strategy to improve anti-tumour immune responses, we injected wild-type C57BL/6 mice with OVA-expressing melanoma (B16 F10 OVA) tumours, and following lymphodepletion, treated them with either PBS (control) or activated WT, FIH KO, VHL KO or FIH/VHL KO OT-I T cells (Figure 4G, Supplementary Figure 4A).